Cargando…

The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status

Background: There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). Methods: The correlation among EMAST status, microsatellite instability (MSI) status...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wen-Liang, Chen, Ming-Huang, Huang, Kuo-Hung, Chang, Shih-Ching, Lin, Chien-Hsing, Chao, Yee, Lo, Su-Shun, Li, Anna Fen-Yau, Wu, Chew-Wun, Shyr, Yi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139949/
https://www.ncbi.nlm.nih.gov/pubmed/32120855
http://dx.doi.org/10.3390/cancers12030551
_version_ 1783518883983917056
author Fang, Wen-Liang
Chen, Ming-Huang
Huang, Kuo-Hung
Chang, Shih-Ching
Lin, Chien-Hsing
Chao, Yee
Lo, Su-Shun
Li, Anna Fen-Yau
Wu, Chew-Wun
Shyr, Yi-Ming
author_facet Fang, Wen-Liang
Chen, Ming-Huang
Huang, Kuo-Hung
Chang, Shih-Ching
Lin, Chien-Hsing
Chao, Yee
Lo, Su-Shun
Li, Anna Fen-Yau
Wu, Chew-Wun
Shyr, Yi-Ming
author_sort Fang, Wen-Liang
collection PubMed
description Background: There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). Methods: The correlation among EMAST status, microsatellite instability (MSI) status, mutations of common GC-related genes and 16 DNA repair-associated genes, and the clinicopathological features were analyzed. Results: Among the 360 GC patients enrolled, there were 76 (21.1%) with EMAST+ tumors and 284 with EMAST− tumors, and 59 (16.4%) were MSI-high (MSI-H) tumors, and 301 were microsatellite stable (MSS) tumors. Patients with EMAST+ tumors exhibited an earlier pathological T category and had more genetic mutations in the PI3K/AKT pathway, ARID1A and DNA repair-associated genes than those with EMAST− tumors. Patients with MSI-H tumors have more genetic mutations in the PI3K/AKT pathway and DNA repair-associated genes than those with MSS tumors. In the subgroup analysis for MSI-H GC, EMAST+ tumors were associated with earlier pathological T and N categories, earlier TNM stages, higher frequency of DNA-repair-associated genetic mutations, and a better survival rate than EMAST− tumors. Conclusions: PI3K/AKT pathway mutations may play an important role in EMAST+ and/or MSI-H GC. EMAST+/MSI-H tumors seem to represent a different subtype of gastric cancer from EMAST−/MSI-H tumors.
format Online
Article
Text
id pubmed-7139949
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71399492020-04-13 The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status Fang, Wen-Liang Chen, Ming-Huang Huang, Kuo-Hung Chang, Shih-Ching Lin, Chien-Hsing Chao, Yee Lo, Su-Shun Li, Anna Fen-Yau Wu, Chew-Wun Shyr, Yi-Ming Cancers (Basel) Article Background: There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). Methods: The correlation among EMAST status, microsatellite instability (MSI) status, mutations of common GC-related genes and 16 DNA repair-associated genes, and the clinicopathological features were analyzed. Results: Among the 360 GC patients enrolled, there were 76 (21.1%) with EMAST+ tumors and 284 with EMAST− tumors, and 59 (16.4%) were MSI-high (MSI-H) tumors, and 301 were microsatellite stable (MSS) tumors. Patients with EMAST+ tumors exhibited an earlier pathological T category and had more genetic mutations in the PI3K/AKT pathway, ARID1A and DNA repair-associated genes than those with EMAST− tumors. Patients with MSI-H tumors have more genetic mutations in the PI3K/AKT pathway and DNA repair-associated genes than those with MSS tumors. In the subgroup analysis for MSI-H GC, EMAST+ tumors were associated with earlier pathological T and N categories, earlier TNM stages, higher frequency of DNA-repair-associated genetic mutations, and a better survival rate than EMAST− tumors. Conclusions: PI3K/AKT pathway mutations may play an important role in EMAST+ and/or MSI-H GC. EMAST+/MSI-H tumors seem to represent a different subtype of gastric cancer from EMAST−/MSI-H tumors. MDPI 2020-02-27 /pmc/articles/PMC7139949/ /pubmed/32120855 http://dx.doi.org/10.3390/cancers12030551 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fang, Wen-Liang
Chen, Ming-Huang
Huang, Kuo-Hung
Chang, Shih-Ching
Lin, Chien-Hsing
Chao, Yee
Lo, Su-Shun
Li, Anna Fen-Yau
Wu, Chew-Wun
Shyr, Yi-Ming
The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
title The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
title_full The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
title_fullStr The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
title_full_unstemmed The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
title_short The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
title_sort clinicopathological features and genetic mutations in gastric cancer patients according to emast and msi status
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139949/
https://www.ncbi.nlm.nih.gov/pubmed/32120855
http://dx.doi.org/10.3390/cancers12030551
work_keys_str_mv AT fangwenliang theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT chenminghuang theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT huangkuohung theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT changshihching theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT linchienhsing theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT chaoyee theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT losushun theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT liannafenyau theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT wuchewwun theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT shyryiming theclinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT fangwenliang clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT chenminghuang clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT huangkuohung clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT changshihching clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT linchienhsing clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT chaoyee clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT losushun clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT liannafenyau clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT wuchewwun clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus
AT shyryiming clinicopathologicalfeaturesandgeneticmutationsingastriccancerpatientsaccordingtoemastandmsistatus